News Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP) Feb 22, 2023 Posted by FERRER INTERNACIONAL
News Syneos Health Dealmakers’ Intentions Survey Sees “Optimism” for M&A Licensing Deals for 2023 Feb 16, 2023
News Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies Feb 16, 2023